Plasma pTau181 and Neuropsychiatric Symptoms in Alzheimer’s Dementia: Insights from a Cross-Sectional Study
Article Sidebar
Main Article Content
Page: 2502-2511
Abstract
Alzheimer’s disease is the leading cause of dementia, marked by progressive cognitive decline and neuropsychiatric disturbances collectively known as behavioral and psychological symptoms of dementia (BPSD). Plasma phosphorylated tau at threonine-181 (pTau181) has emerged as a minimally invasive biomarker of tau-related neurodegeneration, but its association with BPSD remains uncertain. This study investigated the relationship between plasma pTau181 levels and BPSD in Alzheimer’s dementia. An analytical observational study with a cross-sectional design was conducted in patients clinically diagnosed with predefined eligibility criteria. Plasma pTau181 concentrations were measured using enzyme-linked immunosorbent assay (ELISA), while BPSD was assessed using the Neuropsychiatric Inventory Questionnaire (NPI-Q). Statistical analyses were performed to examine associations between plasma pTau181 and BPSD status. Plasma pTau181 levels ranged from 4.32 to 97.23 pg/mL, with a median plasma pTau181 level of 19.29 pg/mL (IQR: 11.81-25.05) in patients without BPSD and 20.67 pg/mL (IQR: 11.81-43.41) in those with BPSD. No significant differences in pTau181 levels were observed between patients with and without BPSD (p = 0.310). These findings suggest that plasma pTau181 may not be directly related to the presence of BPSD in Alzheimer’s dementia. While plasma pTau181 remains a promising biomarker of tau pathology, its predictive value for neuropsychiatric symptoms appears limited. Longitudinal studies are needed to explore its role in BPSD pathophysiology further.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
Ropper AH, Samuels MA, Klein JP, et al. Adams and Victor’s Principles of Neurology. Adams Victor’s Princ. Neurol. 12e. 12th ed., New York, NY: McGraw-Hill Education; 2023, p. 575.
Kumar A, Sidhu J;, Goyal A, et al. Alzheimer Disease. StatPearls Publ 2022. https://www.ncbi.nlm.nih.gov/books/NBK499922/ (accessed May 10, 2024).
Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer’s disease. Lancet 2021;397:1577–90. https://doi.org/10.1016/S0140-6736(20)32205-4. DOI: https://doi.org/10.1016/S0140-6736(20)32205-4
Alzheimer's Association. Alzheimer’s Disease Facts and Figures. Alzheimer's Assoc 2025. https://www.alz.org/getmedia/ef8f48f9-ad36-48ea-87f9-b74034635c1e/alzheimers-facts-and-figures.pdf.
Nugraha S, Tondokoro T, Susilowati IH, et al. Knowledge about Dementia and its Associated Factors: Study among the Middle-aged Population in Indonesia. Open Access Maced J Med Sci 2022;10:783–9. https://doi.org/10.3889/oamjms.2022.8892. DOI: https://doi.org/10.3889/oamjms.2022.8892
Farina N, Jacobs R, Turana Y, et al. Comprehensive measurement of the prevalence of dementia in low- and middle-income countries: STRiDE methodology and its application in Indonesia and South Africa. BJPsych Open 2023;9:1–7. https://doi.org/10.1192/bjo.2023.76. DOI: https://doi.org/10.1192/bjo.2023.76
Huang SS, Wang WF, Liao YC. Severity and prevalence of behavioral and psychological symptoms among patients of different dementia stages in Taiwan. Rev Psiquiatr Clin 2017;44:89–93. https://doi.org/10.1590/0101-60830000000127. DOI: https://doi.org/10.1590/0101-60830000000127
Tissot C, Therriault J, Pascoal TA, et al. Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer’s disease. Alzheimer’s Dement Transl Res Clin Interv 2021;7:1–11. https://doi.org/10.1002/trc2.12154. DOI: https://doi.org/10.1002/trc2.12154
Arenare G, Manca R, Caffarra P, et al. Associations between Neuropsychiatric Symptoms and Alzheimer’s Disease Biomarkers in People with Mild Cognitive Impairment. Brain Sci 2023;13:1195. https://doi.org/10.3390/brainsci13081195. DOI: https://doi.org/10.3390/brainsci13081195
Cloak N, Al Khalili Y. Behavioral and Psychological Symptoms in Dementia. StatPearls Publ 2022. https://www.ncbi.nlm.nih.gov/books/NBK551552/ (accessed May 10, 2024).
Meng J, Lei P. Plasma pTau181 as a biomarker for Alzheimer’s disease. MedComm 2020;1:74–6. https://doi.org/10.1002/mco2.1. DOI: https://doi.org/10.1002/mco2.1
Moscoso A, Grothe MJ, Ashton NJ, et al. Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum. Brain 2021;144:325–39. https://doi.org/10.1093/brain/awaa399. DOI: https://doi.org/10.1093/brain/awaa399
Thijssen EH, La Joie R, Wolf A, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration. Nat Med 2020;26:387–97. https://doi.org/10.1038/s41591-020-0762-2. DOI: https://doi.org/10.1038/s41591-020-0762-2
Babulal GM, Ghoshal N, Head D, et al. Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer's Disease Biomarker Levels. Am J Geriatr Psychiatry 2016;24:1095–104. https://doi.org/10.1016/j.jagp.2016.04.004. DOI: https://doi.org/10.1016/j.jagp.2016.04.004
Showraki A, Murari G, Ismail Z, et al. Cerebrospinal Fluid Correlates of Neuropsychiatric Symptoms in Patients with Alzheimer’s Disease/Mild Cognitive Impairment: A Systematic Review. J Alzheimer’s Dis 2019;71:477–501. https://doi.org/10.3233/JAD-190365. DOI: https://doi.org/10.3233/JAD-190365
Ng KP, Pascoal TA, Mathotaarachchi S, et al. Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer’s disease. Transl Neurodegener 2021;10:1–11. https://doi.org/10.1186/s40035-020-00225-y. DOI: https://doi.org/10.1186/s40035-020-00225-y
Banning LCP, Ramakers IHGB, Köhler S, et al. The Association Between Biomarkers and Neuropsychiatric Symptoms Across the Alzheimer’s Disease Spectrum. Am J Geriatr Psychiatry 2020;28:735–44. https://doi.org/10.1016/j.jagp.2020.01.012. DOI: https://doi.org/10.1016/j.jagp.2020.01.012
Krell-Roesch J, Zaniletti I, Syrjanen JA, et al. Plasma-derived biomarkers of Alzheimer’s disease and neuropsychiatric symptoms: A community-based study. Alzheimer’s Dement Diagnosis, Assess Dis Monit 2023;15:1–11. https://doi.org/10.1002/dad2.12461. DOI: https://doi.org/10.1002/dad2.12461
McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement 2011;7:263–9. https://doi.org/10.1016/j.jalz.2011.03.005. DOI: https://doi.org/10.1016/j.jalz.2011.03.005
Rabl M, Clark C, Dayon L, et al. Neuropsychiatric symptoms in cognitive decline and Alzheimer’s disease: biomarker discovery using plasma proteomics. J Neurol Neurosurg Psychiatry 2024:jnnp-2024-333819. https://doi.org/10.1136/jnnp-2024-333819. DOI: https://doi.org/10.1136/jnnp-2024-333819
Husein N, Lumempouw SF, Ramli Y, et al. MONTREAL COGNITIVE ASSESSMENT VERSI INDONESIA MoCAIna UNTUK SKRINING GANGGUAN FUNGSI KOGNITIF. Neurona 2010;27.
Morris JC. The clinical dementia rating (CDR): Current version and scoring rules. Neurology 1993;43:2412–4. https://doi.org/10.1212/wnl.43.11.2412-a. DOI: https://doi.org/10.1212/WNL.43.11.2412-a
Murda BKK. Uji Validitas dan Reliabilitas Instrumen Neuropsychiatric Inventory Questionnaire Versi Bahasa Indonesia. Universitas Sebelas Maret, 2023.
Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. Front Neurol 2012; MAY:1–21. https://doi.org/10.3389/fneur.2012.00073. DOI: https://doi.org/10.3389/fneur.2012.00073
Liang C, Yan X, Tian J, et al. Plasma GFAP, NfL, and p-tau181 levels as early biomarkers of dementia in Chinese adults: Shenzhen community cohort study. Aging Clin Exp Res 2025;37:1–8. https://doi.org/10.1007/s40520-025-03001-y. DOI: https://doi.org/10.1007/s40520-025-03001-y
Mendez MF. Early-onset Alzheimer's disease and its variants. Contin Lifelong Learn Neurol 2019;25:34–51. https://doi.org/10.1212/CON.0000000000000687. DOI: https://doi.org/10.1212/CON.0000000000000687
Bassiony MM, Steinberg MS, Warren A, et al. Delusions and hallucinations in Alzheimer’s disease: prevalence and clinical correlates. Int J Geriatr Psychiatry 2000;15:99–107. https://doi.org/10.1002/(SICI)1099-1166(200002)15:2<99::AID-GPS82>3.0.CO;2-5. DOI: https://doi.org/10.1002/(SICI)1099-1166(200002)15:2<99::AID-GPS82>3.3.CO;2-X
Gilley DW, Wilson RS, Bienias JL, et al. Predictors of Depressive Symptoms in Persons With Alzheimer’s Disease. Journals Gerontol Ser B Psychol Sci Soc Sci 2004;59:P75–83. https://doi.org/10.1093/geronb/59.2.P75. DOI: https://doi.org/10.1093/geronb/59.2.P75
Starkstein SE. A prospective longitudinal study of apathy in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2006;77:8–11. https://doi.org/10.1136/jnnp.2005.069575. DOI: https://doi.org/10.1136/jnnp.2005.069575
Deo VK, Singh KK, Sinha N, et al. Correlation of behavioral and psychological symptoms of dementia with patients’ sociodemographic & and clinical details and caregivers’ distress. Ind Psychiatry J 2024;33:101–7. https://doi.org/10.4103/ipj.ipj_137_23. DOI: https://doi.org/10.4103/ipj.ipj_137_23
Saldanha D, Mani RN, Mujawar S, et al. A study of dementia in nursing homes. Ind Psychiatry J 2021;30:S149 54. https://doi.org/10.4103/0972-6748.328806. DOI: https://doi.org/10.4103/0972-6748.328806
Steinberg M, Corcoran C, Tschanz JT, et al. Risk factors for neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry 2006;21:824–30. https://doi.org/10.1002/gps.1567. DOI: https://doi.org/10.1002/gps.1567
Jung G, Lee J. Behavioral and Psychological Symptoms and Associated Factors in Community-Dwelling Persons at the First Time of Dementia Diagnosis. Int J Environ Res Public Health 2022;19. https://doi.org/10.3390/ijerph19137765. DOI: https://doi.org/10.3390/ijerph19137765
Kazui H, Yoshiyama K, Kanemoto H, et al. Differences in behavioral and psychological symptoms of dementia in disease severity in four major dementias. PLoS One 2016;11:1–16. https://doi.org/10.1371/journal.pone.0161092. DOI: https://doi.org/10.1371/journal.pone.0161092
Laganà V, Bruno F, Altomari N, et al. Neuropsychiatric or Behavioral and Psychological Symptoms of Dementia (BPSD): Focus on Prevalence and Natural History in Alzheimer’s Disease and Frontotemporal Dementia. Front Neurol 2022;13. https://doi.org/10.3389/fneur.2022.832199. DOI: https://doi.org/10.3389/fneur.2022.832199
Yan K, He S, Jia X, et al. The diagnostic value of plasma phosphorylated tau 181 in Alzheimer’s disease within the Chinese population: A systematic review and meta-analysis 2024. https://doi.org/10.1101/2024.08.15.24312085. DOI: https://doi.org/10.1101/2024.08.15.24312085
Cooper JG, Stukas S, Ghodsi M, et al. Age-specific reference intervals for plasma biomarkers of neurodegeneration and neurotrauma in a Canadian population. Clin Biochem 2023;121–122:110680. https://doi.org/10.1016/j.clinbiochem.2023.110680. DOI: https://doi.org/10.1016/j.clinbiochem.2023.110680
Mielke MM, Hagen CE, Xu J, et al. Plasma phospho‐tau181 increases with Alzheimer’s disease clinical severity and is associated with tau‐ and amyloid‐positron emission tomography. Alzheimer’s Dement 2018;14:989–97. https://doi.org/10.1016/j.jalz.2018.02.013. DOI: https://doi.org/10.1016/j.jalz.2018.02.013
Ghahremani M, Wang M, Chen HY, et al. Plasma Phosphorylated Tau at Threonine 181 and Neuropsychiatric Symptoms in Preclinical and Prodromal Alzheimer Disease. Neurology 2023;100:E683–93. https://doi.org/10.1212/WNL.0000000000201517. DOI: https://doi.org/10.1212/WNL.0000000000201517